|
|
2008年从癌基因及相关基因国家重点实验室(上海市肿瘤研究所)获复旦大学博士学位。2009至2012年在美国德州大学M.D.安德森癌症中心分子遗传系从事博士后研究。2012年进入复旦大学附属肿瘤医院/肿瘤研究所工作,现为研究员,硕士生导师;担任精准肿瘤中心副主任、肿瘤研究所所长助理、上海市乳腺肿瘤重点实验室秘书等职务。主要从事乳腺癌肿瘤基因组学、肿瘤耐药机制研究、DNA损伤和修复以及高通量文库筛选方向的研究,主要研究成果发表在Cancer Cell, Cell Research, Nature Commun, Hepatology,
Cancer Res, JBC 等国际期刊。获得上海市青年科技“启明星”、复旦大学附属肿瘤医院“优秀硕士生导师”、“十大医务青年”称号。
研究领域:
1.乳腺癌肿瘤基因组学;
2.肿瘤耐药机制研究;
3.DNA损伤修复研究;
4.高通量文库筛选。
代表性论著:
-
Wang
D#, Hu X#, Liu C, Jia Y, Bai Y, Cai
C, Wang J, Bai L, Yang R, Lin C, Liu YR, Li S, Qiao F, Yao L, Chen L, Ge G,
Jiang H, Li D, Li L, Chen J, Shao ZM*, Zeng YA*. Protein C receptor is a therapeutic stem cell target in a
distinct group of breast cancers. Cell Res, 2019 Sep 3. (IF= 17.848)
-
Jiang
YZ#, Ma D#, Suo C#, Shi J#, Xue M#, Hu
X#, Xiao Y, Yu KD, Liu YR, Yu Y, Zheng Y, Li X, Zhang C, Hu P, Zhang J, Hua
Q, Zhang J, Hou W, Ren L, Bao D, Li B, Yang J, Yao L, Zuo WJ, Zhao S, Gong Y,
Ren YX, Zhao YX, Yang YS, Niu Z, Cao ZG, Stover DG, Verschraegen C, Kaklamani
V, Daemen A, Benson JR, Takabe K, Bai F, Li DQ, Wang P*, Shi L*, Huang W*, Shao
ZM*. Genomic and Transcriptomic Landscape of Triple-Negative
Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 2019 Mar 18; 35(3):428-440.e5 (IF= 22.844)
-
Liu Y#, Xue M#, Du S, Feng
W, Zhang K, Zhang L, Liu H, Jia G, Wu L, Hu
X*, Chen L*, Wang P*. Competitive endogenous RNA is an
intrinsic component of EMT regulatory circuits and modulates EMT. Nat Commun,2019 Apr 9; 10(1):1637. (IF=12.124)
-
Chen L#, Yang L#, Yao L#, Kuang XY, Zuo WJ, Li S, Qiao F, Liu YR, Cao ZG, Zhou SL, Zhou XY, Yang WT, Shi JX, Huang W, Hu X*, Shao ZM*. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun, 2018 Apr 10; 9(1):1357. (IF=12.124)
-
Zheng YZ, Xue MZ, Shen HJ,
Li XG, Ma D, Gong Y, Liu YR, Qiao F, Xie HY, Lian B, Sun WL, Zhao HY, Yao L,
Zuo WJ, Li DQ, Wang P, Hu X*, Shao
ZM*. PHF5A Epigenetically Inhibits
Apoptosis to Promote Breast Cancer Progression. Cancer Res, 2018 Jun 15; 78(12):3190-3206 (IF=
9.122)
-
Ye FG#, Song CG#*, Cao ZG,
Xia C, Chen DN, Chen L, Li S, Qiao F, Ling H, Yao L, Hu X*, Shao ZM. Cytidine deaminase axis modulated by miR-484
differentially regulates cell proliferation and chemoresistance in breast
cancer. Cancer Res, 2015 Apr 1; 75(7):1504-15. (IF= 9.122)
-
Kuang XY#, Jiang HS#, Li K,
Zheng YZ, Liu YR, Qiao F, Li S, Hu X*, Shao ZM*. The phosphorylation-specific
association of STMN1 with GRP78 promotes breast cancer metastasis. Cancer Lett, 2016 Jul 0; 377(1):87-96. (F1000)(IF=
6.375)
-
Hu
X#, Zhao Y#, He X, Li J, Wang T, Zhou W, Wan D, Wang H, Gu J*. Ciliary
neurotrophic factor receptor alpha subunit-modulated multiple downstream
signaling pathways in hepatic cancer cell lines and their biological
implications. Hepatology, 2008 Apr; 47(4):1298-308. (IF= 11.36)
-
Hu X, Paul A, Wang B. Rap80 Protein Recruitment to DNA Double-strand Breaks Requires
Binding to Both Small Ubiquitin-like Modifier (SUMO) and Ubiquitin Conjugates. J Biol Chem, 2012 Jul 20; 287(30):25510-9. (IF= 4.77)
-
Hu X, Kim J, Castillo A, Huang M, Liu J, Wang B*. NBA1/Merit40 and BRE interaction is required for the
integrity of two distinct deubiqutinating enzyme BRCC36 containing complexes. J Biol Chem, 2011 Apr 1; 286(13):11734-45. (IF=4.77) (F1000)
|